January 2020
-
Media ReleaseSandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicinesSuccessful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicines Acquired portfolio…
-
Media ReleaseSandoz officially recognized as Global Top Employer 2020Sandoz officially recognized by Top Employers Institute for its exceptional employee offerings globally People-first policies such as global equal parental leave for 14 weeks and joining the Equal…
-
Media ReleaseNovartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and…
November 2019
-
Media ReleaseSandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatmentInterim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when…
-
Media ReleaseSandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics marketPlanned acquisition reinforces Sandoz strategic focus on Japan Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands Medicines…
-
Media ReleaseSandoz receives US FDA approval for long-acting oncology supportive care biosimilar ZiextenzoTM (pegfilgrastim-bmez)Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only company to offer…
July 2019
-
Media ReleaseSandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosisIntegrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine1 Osteoporosis accounts for 8.9m bone fractures…
-
Media ReleaseNovartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increasedContinuing operations1 net sales up 8% (cc2, +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +81% (…
-
Media ReleaseSandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicineAdult and pediatric doses immediately available as single-dose, pre-filled syringe and device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis1 SYMJEPI will…